jueves, 1 de agosto de 2013

National Guideline Clearinghouse | Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

full-text ►
National Guideline Clearinghouse | Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

National Guideline Clearinghouse (NGC)

July 29, 2013



Guideline Title
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
 
Bibliographic Source(s)
Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S, Italian Society of Hematology. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.  Leuk Res. 2010 Dec;34(12):1576-88. [167 references] PubMed External Web Site Policy
 
Guideline Status
This is the current release of the guideline.


Clinical management of myelodysplastic syndromes: u... [Leuk Res. 2010] - PubMed - NCBI
Leuk Res. 2010 Dec;34(12):1576-88. doi: 10.1016/j.leukres.2010.01.018. Epub 2010 Feb 11.

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

Source

Functional Unit of Haematology, AOU Careggi, University of Florence, Firenze, Italy. santini@unifi.it

Abstract

Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update. After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence. The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb <10 allogeneic="" and="" co="" dl="" endogenous="" epo="" first-line="" for="" g="" high-risk="" hsct="" int2-="" l="" morbidities.="" p="" patients="" severe="" therapy="" u="" without="" years="">Copyright © 2010 Elsevier Ltd. All rights reserved.
PMID:
20149927
[PubMed - indexed for MEDLINE] 
 Clinical management of myelodysplastic syndromes: u... [Leuk Res. 2010] - PubMed - NCBI

No hay comentarios:

Publicar un comentario